HU

Hutchmed (China) Limited

Overview

Corporate Details

ISIN(s):
KYG4672N1198 (+1 more)
LEI:
2138006X34YDQ6OBYE79
Country:
Hong Kong
Address:
LEVEL 18, THE METROPOLIS TOWER, KOWLOON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

No description available.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Hutchmed (China) Limited. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-26 08:00
Board/Management Information
Directorate Change
English 17.9 KB
2025-08-20 08:00
Regulatory News Service
HUTCHMED Completes Enrollment of Phase III Trial
English 29.1 KB
2025-08-07 13:00
Earnings Release
2025 Interim Results
English 141.5 KB
2025-07-03 10:30
Report Publication Announcement
HUTCHMED to Announce 2025 Half-Year Results
English 12.1 KB
2025-06-30 10:30
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 12.4 KB
2025-06-30 10:30
Remuneration Information
Blocklisting Six Monthly Return
English 25.1 KB
2025-06-30 10:30
Regulatory News Service
China Approval based on Phase III SACHI Trial
English 29.8 KB

Automate Your Workflow. Get a real-time feed of all Hutchmed (China) Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Hutchmed (China) Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
HISAMITSU PHARMACEUTICAL CO.,INC. Logo Japan 4530
H. Lundbeck A Logo
Global pharmaceutical company creating innovative treatments for brain diseases.
Denmark HLUN
Hyloris Pharmaceuticals SA Logo
A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.
Belgium HYL
Idorsia Ltd Logo
Develops novel medicines for CNS, cardiovascular, immunological, and orphan diseases.
Switzerland IDIA
Immuno-Biological Laboratories Co., Ltd. Logo Japan 4570
Indivior PLC Logo
A global pharmaceutical firm developing treatments for addiction and mental illness.
United Kingdom INDV
Infant Bacterial Therapeutics Logo
Developing microbiome therapies for premature infants to prevent life-threatening intestinal disease.
Sweden IBT
Intercure Ltd. Logo
Producer of pharma-grade, GMP-certified medical cannabis products for patients outside North America.
Israel INCR
Intervacc AB Logo
Develops recombinant protein vaccines for animal health, led by its vaccine for equine strangles.
Sweden IVACC
Ipsen Logo
Develops transformative medicines for Oncology, Rare Diseases, and Neuroscience.
France IPN